[go: up one dir, main page]

IL281281A - Combined treatment for prostate cancer - Google Patents

Combined treatment for prostate cancer

Info

Publication number
IL281281A
IL281281A IL281281A IL28128121A IL281281A IL 281281 A IL281281 A IL 281281A IL 281281 A IL281281 A IL 281281A IL 28128121 A IL28128121 A IL 28128121A IL 281281 A IL281281 A IL 281281A
Authority
IL
Israel
Prior art keywords
prostate cancer
combined treatment
treatment
combined
prostate
Prior art date
Application number
IL281281A
Other languages
Hebrew (he)
Other versions
IL281281B1 (en
Original Assignee
Zenith Epigenetics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zenith Epigenetics Ltd filed Critical Zenith Epigenetics Ltd
Publication of IL281281A publication Critical patent/IL281281A/en
Publication of IL281281B1 publication Critical patent/IL281281B1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41661,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/422Oxazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
IL281281A 2018-09-13 2021-03-04 Combination containing a bromodomain levothyroxine inhibitor for the treatment of prostate cancer IL281281B1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862730869P 2018-09-13 2018-09-13
US201862737612P 2018-09-27 2018-09-27
US201862778185P 2018-12-11 2018-12-11
PCT/US2019/050970 WO2020056232A1 (en) 2018-09-13 2019-09-13 Combination therapy for the treatment of prostate cancer

Publications (2)

Publication Number Publication Date
IL281281A true IL281281A (en) 2021-04-29
IL281281B1 IL281281B1 (en) 2025-11-01

Family

ID=69778254

Family Applications (1)

Application Number Title Priority Date Filing Date
IL281281A IL281281B1 (en) 2018-09-13 2021-03-04 Combination containing a bromodomain levothyroxine inhibitor for the treatment of prostate cancer

Country Status (12)

Country Link
US (1) US20220117942A1 (en)
EP (1) EP3849544A4 (en)
JP (1) JP7441214B2 (en)
KR (1) KR102844523B1 (en)
CN (1) CN112912075B (en)
AU (1) AU2019338483B2 (en)
CA (1) CA3112396A1 (en)
IL (1) IL281281B1 (en)
MX (1) MX2021002884A (en)
SG (1) SG11202102492PA (en)
TW (1) TWI816880B (en)
WO (1) WO2020056232A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI882964B (en) 2018-09-13 2025-05-11 大陸商恒翼生物醫藥(上海)股份有限公司 Method of manufacturing a solid form of a bet bromodomain inhibitor
EP4294397A1 (en) * 2021-02-22 2023-12-27 Celgene Quanticel Research, Inc. Bromodomain (bet) inhibitor for use in treating prostate cancer
CN114644687B (en) * 2022-04-07 2023-06-27 华中科技大学同济医学院附属协和医院 Polypeptide RBIP-21 capable of antagonizing RBM25 protein RNA binding activity and application thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0919434D0 (en) * 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
EP2621483A1 (en) * 2010-09-27 2013-08-07 Exelixis, Inc. Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases
ES2806135T3 (en) 2013-06-21 2021-02-16 Zenith Epigenetics Ltd New bicyclic bromodomain inhibitors
JP6548641B2 (en) * 2013-10-28 2019-07-24 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Treatment of metastatic prostate cancer
NO2719005T3 (en) * 2014-07-28 2018-01-20
WO2016171470A1 (en) * 2015-04-21 2016-10-27 Kainos Medicine, Inc. Bromodomain-inhibiting compounds and methods to prevent or treat a cancer
US20190134004A1 (en) * 2016-06-16 2019-05-09 The University Of Chicago Methods and compositions for treating breast and prostate cancer
US20180141939A1 (en) * 2016-11-22 2018-05-24 Gilead Sciences, Inc. Solid forms of a bet inhibitor
WO2018106433A1 (en) * 2016-12-06 2018-06-14 Gilead Sciences, Inc. Treatment of prostate cancer by concomitant administration of a bromodomain inhibitor and a second agent

Also Published As

Publication number Publication date
IL281281B1 (en) 2025-11-01
MX2021002884A (en) 2021-07-15
AU2019338483B2 (en) 2025-01-02
US20220117942A1 (en) 2022-04-21
KR102844523B1 (en) 2025-08-12
TW202017926A (en) 2020-05-16
AU2019338483A1 (en) 2021-04-08
CA3112396A1 (en) 2020-03-19
WO2020056232A1 (en) 2020-03-19
KR20210060515A (en) 2021-05-26
CN112912075B (en) 2023-04-04
JP2022500431A (en) 2022-01-04
TWI816880B (en) 2023-10-01
EP3849544A4 (en) 2022-06-08
SG11202102492PA (en) 2021-04-29
CN112912075A (en) 2021-06-04
EP3849544A1 (en) 2021-07-21
JP7441214B2 (en) 2024-02-29

Similar Documents

Publication Publication Date Title
IL269026A (en) Tumor treatment methods
IL282663A (en) BT1718 for use in cancer treatment
HUE053191T2 (en) 2-Heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer
IL260444B (en) Anti-her2 combinations for cancer treatment
IL265697B1 (en) Prostate cancer treatment
IL284875A (en) Zofoxifene treatment for breast cancer
IL264443A (en) Prostate cancer treatment methods
DK3768830T5 (en) CANCER THERAPY
KR20180084772A (en) Combination Therapy for Cancer Treatment
PL3622953T3 (en) Combined cancer therapy
MA48728A (en) POLYTHERAPY AGAINST PROSTATE CANCER
DK3576740T3 (en) CANCER TREATMENT
EP3413927A4 (en) Cancer Therapy
IL281845A (en) Combined treatment for cancer
GB201820660D0 (en) Cancer treatments
IL264589A (en) Combined treatment for pancreatic cancer
EP3576791A4 (en) CALRETICULIN-MEDIATED CANCER TREATMENT
IL308399A (en) Cancer treatment methods
IL281600A (en) Cancer treatment methods
LT3534885T (en) PHARNESYL TRANSANSERASE INHIBITORS FOR THE TREATMENT OF CANCER
HUE053648T2 (en) Therapeutic combinations for the treatment of cancer
EP3568694A4 (en) TARGETED DOXORUBICIN-GOLD NANOCONJUGATES FOR TUMOR THERAPY
IL281281A (en) Combined treatment for prostate cancer
EP3791877A4 (en) PROPHYLACTIC OR THERAPEUTIC FOR PROSTATE CANCER
EP4025203A4 (en) CANCER TREATMENT